Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
13F holders, Q1 2025 (March 31)1holders −3
0new positions
3sold out
$1.03avg. 13F price*
At the end of Q1 2025, 1 institutions reported holding Travere Therapeutics Inc. (tvtx 2.25 03/01/29) in their 13F filings, down 3 from Q4 2024. 0 opened new positions and 3 sold out. The largest holder was Janus Henderson Group PLC ($10.7M).
- Company
- Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
- CUSIP
- 89422GAA5
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $2.5M |
All 13F filers, Q4 2024 → Q1 2025: 5,623,000 shares bought and 2,350,479 shares sold, net +3,272,521 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Janus Henderson Group PLC | 0.01% | Add +117.9% | 10,394,000 | $10.7M |
"% of holder's portfolio" is TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29)'s weight in each manager's 13F, not the share of Travere Therapeutics Inc. (tvtx 2.25 03/01/29) the manager owns.